Hydroxychloroquine combination risky for cancer patients with COVID-19: study

Hydroxychloroquine combination risky for cancer patients with COVID-19: study

Reuters

Published

Cancer patients with COVID-19 who were treated with a drug combination promoted by U.S. President Donald Trump to counter the coronavirus were three times more likely to die within 30 days than those who got either drug alone, U.S. researchers reported on Thursday.

Full Article